Figure 1. Pargyline promotes inhibitory epigenetic modifi cations. (A) MCF-7-PELP1 cells and (B)
MCF-7-HER2 cells were treated with pargyline (3 mM), and chromatin immunoprecipitation analysis was performed using H3K4me2-specifi c, H3K9me2-specifi c or H3K9ac-specifi c antibodies and the status of epigenetic modifi cations was analyzed using real-time PCR with the estrogen receptor target gene GREB1C proximal promoterspecifi c primers (B). Immunohistochemistry analysis of indicated epigenetic marks was done on (C) MCF-7 and (D) MCF-7-PELP1 xenografts that were treated with or without pargyline. Representative images are shown. Quantitation of staining performed as described in Materials and methods. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. PAR, pargyline; PELP1, proline glutamic acid and leucine-rich protein 1.
